Eli Lilly and Co
(MEX:LLY)
MXN
16200
-45 (-0.28%)
Market Cap: 15.40 Tn
Enterprise Value: 15.95 Tn
PE Ratio: 86.91
PB Ratio: 50.80
GF Score: 81/100 
Eli Lilly and Co at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 13, 2019 / 03:35PM GMT
Release Date Price:
MXN2170
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst
© -
Excellent. Hi, there. My name is Evan Seigerman. I'm the senior large-cap biotechnology analyst here at Crédit Suisse. And I also have my colleague, Matt Weston, from the European pharma team.
Matthew Weston;dit Suisse AG
CrÃ;Research Division - MD and Co-Head of European Pharmaceutical Equity Research
© -
Good morning, everybody.
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst
© -
And it is my pleasure to have Eli Lilly with us today. And from Eli Lilly, we have Anne White, SVP and President of Lilly Oncology; Maura Dickler, VP, Oncology Late-Phase Development; and Kim Blackwell, VP, Early-Phase Clinical Development. Thank you for coming to Scottsdale.
Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology
It's our
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers